Home World News Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients... World News Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin By Ogkologos - February 23, 2026 382 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR The vaccination of a generation? – That Cancer Conversation December 9, 2021 FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma July 12, 2022 Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... September 20, 2024 Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated... April 1, 2025 Load more HOT NEWS Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... 2021/22 in review: Charity looks to the future with ambitious new... Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth
